Tumor-derived vaccines containing CD200 inhibit immune activation: Implications for immunotherapy

Zhengming Xiong, Elisabet Ampudia-Mesias, Rob Shaver, Craig M. Horbinski, Christopher L. Moertel, Michael R. Olin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


There are over 400 ongoing clinical trials using tumor-derived vaccines. This approach is especially attractive for many types of brain tumors, including glioblastoma, yet so far the clinical response is highly variable. One contributor to poor response is CD200, which acts as a checkpoint blockade, inducing immune tolerance. We demonstrate that, in response to vaccination, glioma-derived CD200 suppresses the anti-tumor immune response. In contrast, a CD200 peptide inhibitor that activates antigen-presenting cells overcomes immune tolerance. The addition of the CD200 inhibitor significantly increased leukocyte infiltration into the vaccine site, cytokine and chemokine production, and cytolytic activity. Our data therefore suggest that CD200 suppresses the immune system's response to vaccines, and that blocking CD200 could improve the efficacy of cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)1059-1071
Number of pages13
Issue number9
StatePublished - Sep 2016


  • CD200 protein
  • checkpoint blockade
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Tumor-derived vaccines containing CD200 inhibit immune activation: Implications for immunotherapy'. Together they form a unique fingerprint.

Cite this